Following a challenging two-year downturn, private biopharmaceutical venture financing saw a 20% ($3.8 million) increase in total deal value from 2023 to $22.4 million in 2024 year-to-date (YTD), according to GlobalData’s Pharma Intelligence Center deals database. This growth is an encouraging sign of recovery driven by improving investor confidence.
The downturn that began in 2022 followed a peak in venture financing in 2021. During this period, many early-stage biotech companies went public with inflated valuations, leading to a more cautious investment environment. Factors contributing to this downturn included geopolitical challenges, rising inflation and high interest rates, all of which tightened funding conditions. These challenges emphasised the need for stabilisation in the market to regain investor confidence.
Investor sentiment began to improve in 2024, bolstered by economic and monetary policy shifts. The stabilisation of inflation allowed central banks, including the US Federal Reserve, to lower interest rates. This reduction in the cost of capital has made biotech investments more attractive. Notably, 2024 has seen larger funding rounds compared to the smaller deals of previous years, signaling increased confidence in the sector’s long-term potential.
Despite the upswing, investors’ caution persists. At GlobalData’s Pharma Conference 2024: Cell and Gene Therapies: Current and Future Landscape conference in November 2024, Sharon Cartic, director of drugs and business fundamentals at GlobalData, revealed that 166 out of 785 US venture-backed companies with an innovator drug in clinical development have not raised capital since 2021. These companies are likely to actively seek funding as market conditions continue to improve. Among the companies that secured financing, venture funding values saw a 46% increase, marking the highest growth observed across Europe and Asia-Pacific.
The recovery in venture financing is reflected in a resurgence of initial public offerings (IPOs). Both the volume and value of IPOs have risen in 2024, signaling the reopening of a market that has been constrained by high interest rates and economic uncertainty in recent years. The US Federal Reserve’s decision to lower interest rates has been pivotal to this revival, fostering a more favourable climate for biotech companies to go public and secure new investments.
While the recovery is encouraging, President-elect Donald Trump’s return to leadership introduces uncertainty. The Trump administration’s deregulatory approach could lead to unpredictability in healthcare policies, particularly around drug pricing reforms and regulatory frameworks. Additionally, the geopolitical tensions and economic volatility associated with such policy shifts may impact investor confidence, affecting funding for existing companies, new market entrants and overall innovation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData